vida: extract claims from 2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud

- Source: inbox/queue/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md
- Domain: health
- Claims: 2, Entities: 1
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/ibogaine-oud-evidence-strongest-psychedelic-addiction-application-but-cardiac-safety-delays-approval-4-5-years.md

@@ -0,0 +1,20 @@
+---
+type: claim
+domain: health
+description: "MAPS Phase 2 shows 70-75% abstinence at 1 month with single-dose opioid withdrawal abolition, but QT prolongation risk and >30 deaths require extended safety protocols"
+confidence: experimental
+source: UTMB/UTHealth Texas IMPACT announcement, MAPS Phase 2 data, Stanford 2024 veterans study
+created: 2026-05-11
+title: Ibogaine demonstrates strongest single-session evidence for opioid use disorder among psychedelics but cardiac safety requirements delay FDA approval 4-5 years beyond psilocybin
+agent: vida
+sourced_from: health/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md
+scope: causal
+sourcer: UTMB Health / UTHealth Houston
+supports: ["americas-declining-life-expectancy-is-driven-by-deaths-of-despair-concentrated-in-populations-and-regions-most-damaged-by-economic-restructuring-since-the-1980s"]
+challenges: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access"]
+related: ["psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability", "glp-1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "americas-declining-life-expectancy-is-driven-by-deaths-of-despair-concentrated-in-populations-and-regions-most-damaged-by-economic-restructuring-since-the-1980s", "ibogaine-federal-policy-priority-rests-on-single-n30-pilot-illustrating-veteran-constituency-acceleration-ahead-of-evidence-hierarchy"]
+---
+
+# Ibogaine demonstrates strongest single-session evidence for opioid use disorder among psychedelics but cardiac safety requirements delay FDA approval 4-5 years beyond psilocybin
+
+The Texas IMPACT consortium ($50M state + $50M federal) represents the largest state-sponsored psychedelic research investment targeting opioid use disorder, the highest-mortality addiction crisis (79,384 overdose deaths in 2024). MAPS Phase 2 trials demonstrate 70-75% abstinence at 1 month, and ibogaine uniquely abolishes opioid withdrawal symptoms within 1-2 days through opioid receptor reset and GDNF-mediated dopaminergic neuron regeneration. However, ibogaine remains Schedule I with no completed Phase 3 trial, while psilocybin has two positive Phase 3 trials for treatment-resistant depression with rolling NDA submission Q4 2026. The critical barrier is cardiac safety: ibogaine causes QT prolongation with >30 documented deaths in unsupervised settings, requiring extensive safety protocols that extend the regulatory timeline. Texas IMPACT is Phase 2 scale (multi-site, two-year duration), meaning Phase 3 initiation depends on these results, with realistic NDA submission 2029-2030. The urgency-evidence-access gap is widest for ibogaine: strongest evidence for the most acute crisis, but furthest from approval due to safety requirements that psilocybin's cleaner profile avoids.

domains/health/texas-conservative-state-psychedelic-research-enabled-by-veteran-constituency-transcending-partisan-politics.md

@@ -0,0 +1,18 @@
+---
+type: claim
+domain: health
+description: Texas authorized $50M for ibogaine research through veteran-focused framing (Stanford n=30 study in veterans) where psilocybin depression research might have failed politically
+confidence: experimental
+source: Texas SB 2308 (December 2025), Trump EO April 2026 directing ARPA-H funding toward ibogaine for veterans
+created: 2026-05-11
+title: Conservative state psychedelic research authorization is enabled by veteran constituency that transcends partisan politics rather than general mental health advocacy
+agent: vida
+sourced_from: health/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md
+scope: structural
+sourcer: UTMB Health / UTHealth Houston
+related: ["psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability", "ibogaine-federal-policy-priority-rests-on-single-n30-pilot-illustrating-veteran-constituency-acceleration-ahead-of-evidence-hierarchy", "stanford-ibogaine-veterans-study", "trump-2026-psychedelic-executive-order-creates-bipartisan-regulatory-acceleration-through-existing-frameworks"]
+---
+
+# Conservative state psychedelic research authorization is enabled by veteran constituency that transcends partisan politics rather than general mental health advocacy
+
+Texas represents the most conservative large state in the US, yet authorized $50M for Schedule I psychedelic drug research through SB 2308 in December 2025, with potential $50M federal ARPA-H match directed by Trump executive order in April 2026. The political enabling mechanism is veteran-specific: the Stanford 2024 study (n=30) demonstrated 88% PTSD reduction and 87% depression reduction in veterans specifically, and the Texas IMPACT consortium explicitly targets PTSD and TBI alongside OUD. Veterans represent a constituency that transcends partisan politics in ways that general mental health populations do not. The PTSD+TBI+veteran framing made ibogaine acceptable to Texas Republicans where psilocybin for depression in general populations likely would not have secured equivalent funding. This creates a distinct political pathway for psychedelic research: veteran-focused applications can access conservative state funding and federal support (Trump EO) that wellness or general mental health applications cannot. The Trump administration's ARPA-H directive and DEA rescheduling commitment upon Phase 3 completion further demonstrates bipartisan federal support when framed through veteran health rather than broader mental health reform.

entities/health/texas-impact-consortium.md

@@ -0,0 +1,71 @@
+---
+type: entity
+entity_type: research_program
+name: Texas IMPACT Consortium
+full_name: Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma
+domain: health
+status: active
+founded: 2025-12
+headquarters: Texas, USA
+website: null
+tags: [ibogaine, OUD, PTSD, TBI, psychedelic, clinical-trial, Texas]
+---
+
+## Overview
+
+The Texas IMPACT (Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma) Consortium represents the largest state-sponsored psychedelic research investment in US history, with $50 million from Texas Health and Human Services Commission plus up to $50 million ARPA-H federal match for a potential $100 million total.
+
+## Structure
+
+**Lead institutions:** UTHealth Houston and UTMB Health (Galveston)
+
+**Consortium members (11 institutions):**
+- UTHealth Houston
+- UTMB Health
+- Texas Tech University
+- Texas Tech UTHS El Paso
+- UT Austin
+- UT Health Science Center San Antonio
+- UT Tyler
+- UT Rio Grande Valley
+- Texas A&M University
+- University of North Texas Health Science Center
+- Baylor College of Medicine
+- JPS Health Network (Dallas)
+
+## Research Design
+
+**Duration:** Two-year multicenter trial (Phase 2 scale)
+
+**Conditions targeted:**
+- Opioid use disorder (primary indication) — UTHealth Houston + UTMB
+- Traumatic brain injury — UT Austin + Baylor College of Medicine
+- PTSD — coordinated across sites
+
+**Key evidence basis:**
+- Stanford 2024 study (n=30 veterans): 88% PTSD reduction, 87% depression reduction at 1 month
+- MAPS Phase 2 OUD: 70-75% abstinence at 1 month
+- Mechanism: Opioid receptor reset + GDNF production → dopaminergic neuron regeneration
+- Unique capability: Abolishes opioid withdrawal symptoms within 1-2 days
+
+## Regulatory Context
+
+**Current status:** Ibogaine is Schedule I (federal) with no completed Phase 3 trial in US
+
+**Safety barrier:** QT prolongation risk with >30 documented deaths in unsupervised settings
+
+**Political support:**
+- Texas SB 2308 (December 2025): Authorized $50M state funding
+- Trump EO (April 2026): Directed ARPA-H funding toward ibogaine for veterans; DEA to initiate rescheduling upon Phase 3 completion
+- Colorado Proposition 122: Decriminalized in Colorado
+
+## Timeline
+
+- **2025-12** — Texas SB 2308 authorizes $50M state funding for IMPACT consortium
+- **2026-04** — Trump executive order directs ARPA-H to provide up to $50M federal match and commits DEA to rescheduling process upon Phase 3 completion
+
+## Significance
+
+The Texas IMPACT consortium addresses the opioid overdose crisis (79,384 deaths in 2024), the most acute public health emergency in mental health/substance use. Ibogaine is the only psychedelic with credible single-session evidence for OUD specifically. The program demonstrates bipartisan political support through veteran-focused framing, with conservative Texas authorizing the largest state psychedelic research investment in US history.
+
+Realistic FDA approval timeline: 2029-2030 if Phase 2 data supports Phase 3 advancement, making ibogaine 4-5 years behind psilocybin despite addressing higher-mortality condition.

inbox/archive/health/2025-12-12-utmb-uthealth-texas-ibogaine-impact-50m-oud.md

@@ -7,10 +7,13 @@ date: 2025-12-12
 domain: health
 secondary_domains: []
 format: press-release
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-11
 priority: medium
 tags: [ibogaine, OUD, PTSD, TBI, Texas, clinical-trial, psychedelic, addiction, federal-funding]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content